DNM1L and glaucoma: DRP1 may also serve as an auspicious target for a potential antibody-based therapy for glaucoma, since intravitreal injection of an anti-DRP1 antibody in an animal glaucoma model protected RGCs, decreased apoptosis as shown using western blot analysis, and improved retinal functionality as observed using electroretinography [240].